Heart failure (HF) continues to be a major health problem and is an end-point of cardiac injury, which in many cases is preceded by cardiac hypertrophy and adverse remodeling. We have found that G protein-coupled receptor (GPCR) signaling and regulation of this signaling by GPCR kinases (GRKs) play crucial roles in the pathological processes of maladaptive cardiac hypertrophy and ventricular remodeling. GRK2 and GRKS are the major cardiac GRKs and both have been found to be up-regulated in failing human myocardium so their function in the injured heart is of significance. In the first funding cycle of this Project, we have identified that GRKS plays a novel non-GRK role in cardiomyocyte signaling and function within the nucleus of myocytes acting as a Class II histone deacetylase (HDAC) kinase. This HDAC kinase activity of GRKS can facilitate maladaptive cardiac hypertrophy and accelerate HF development. We now have new preliminary data to suggest there are additional targets within the myocyte for GRKS, including in the nucleus, that can promote myocyte dysfunction. Included is the nuclear factor of activated T-cell (NFAT) pathway and it appears that GRKS can activate this critical molecule in the heart. We will also investigate the role of GRKS in ischemic injury and repair and have assembled several key mouse models and viral constructs to delineate specific pathological and therapeutic mechanisms surrounding this kinase. Included is the development of a novel knock-in mouse where all endogenous GRKS will be defective in its ability to enter the nucleus. Using these we will test the Central Hypothesis that GRKS plays a critical (patho)- physiological role in the cardiomyocyte's response to injury and targeting and manipulating its unique cellular localization and activity is a novel therapeutic strategy for preventing maladaptive cardiac hypertrophy, ventricular remodeling and HF. Our associated Specific Aims to test this hypothesis are:  To determine the mechanisms involved in the GRKS-mediated regulation of cardiac NFAT signaling; To determine the mechanistic role of nuclear GRKS activity in the heart's response to ischemic injury;and  To determine the ultimate physiological role for nuclear GRKS activity and localization in cardiac injury and repair.
Heart failure (HF) is a major health problem throughout the world and understanding molecular processes involved in cardiac injury and repair can advance development of novel therapies. We have found that a specific kinase, GRKS, can play a key role in HF pathogenesis and through continued GRKS-targeted research in this area can lead to translatable strategies to combat cardiac injury HF.
|Ahmad, Firdos; Lal, Hind; Zhou, Jibin et al. (2014) Cardiomyocyte-specific deletion of Gsk3? mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. J Am Coll Cardiol 64:696-706|
|Bathgate-Siryk, Ashley; Dabul, Samalia; Pandya, Krunal et al. (2014) Negative impact of *-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension 63:404-12|
|Scimia, Maria Cecilia; Blass, Benjamin E; Koch, Walter J (2014) Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy. Expert Rev Cardiovasc Ther 12:733-41|
|Lal, Hind; Ahmad, Firdos; Parikh, Shan et al. (2014) Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. Circ J 78:1514-9|
|Hullmann, Jonathan E; Grisanti, Laurel A; Makarewich, Catherine A et al. (2014) GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ Res 115:976-85|
|Miller, Barbara A; Hoffman, Nicholas E; Merali, Salim et al. (2014) TRPM2 channels protect against cardiac ischemia-reperfusion injury: role of mitochondria. J Biol Chem 289:7615-29|
|Tilley, Douglas G; Zhu, Weizhong; Myers, Valerie D et al. (2014) ?-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. Circulation 130:1800-11|
|Feldman, Arthur M; Begay, Rene L; Knezevic, Tijana et al. (2014) Decreased levels of BAG3 in a family with a rare variant and in idiopathic dilated cardiomyopathy. J Cell Physiol 229:1697-702|
|Scimia, Maria C; Gumpert, Anna M; Koch, Walter J (2014) Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 14:183-95|
|Wang, JuFang; Song, Jianliang; Gao, Erhe et al. (2014) Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 306:H1066-77|
Showing the most recent 10 out of 81 publications